JHJens Helby

Jens Helby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jens Helby has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidentally detected thrombocytopenia and risk of haematological disease and death in the general population: prospective cohort study

    by Anne Rudbeck Juhl, Andreas Glenthøj, Børge G Nordestgaard, Jesper Brix Petersen, Morten Dahl, Christina Ellervik, Stig Egil Bojesen, Jens Helby

  • Open Access

    Incidentally detected vertebral fractures and risk of myeloma: a prospective cohort study of 9059 CT-scanned Danish general population individuals

    by Rasmus Rønnemoes, Anne Rudbeck Juhl, Shoaib Afzal, Stig Egil Bojesen, Børge Grønne Nordestgaard, Michael Huy Cuong Pham, Klaus Fuglsang Kofoed, Jørgen Tobias Kühl, Andreas Fuchs Larsen, Per Ejlstrup Sigvardsen, et al.

  • Open Access

    Automated patch clamp supports functional PIEZO1 variant classification in red blood cells in hereditary xerocytosis

    by Kian Haseli, Bo Hjorth Bentzen, Jesper Brix Petersen, Jens Helby, David Van Assche, Andreas Glenthøj, Kim Boddum

  • Open Access

    Coverage of antenatal haemoglobinopathy screening in the Capital Region of Denmark: a laboratory-based evaluation of screening implementation

    by Andreas Glenthøj, Jens Helby, Mathilde Charlotte Schmidt, Maymana Hashim Mohamed Mohamed Salih, Jesper Petersen

    Haemoglobinopathies are among the world’s most common genetic disorders, affecting >5% of the global population [1]. Historically concentrated in malaria-endemic regions, these conditions now pose ...

  • No overall increased risk of death in individuals with sickle cell trait: a study of 467 779 general population adults

    by Marie Warny, Andreas Glenthøj, Shoaib Afzal, Shaodong Wei, Jesper Brix Petersen, Jens Helby

    Uncertainty remains about whether sickle cell trait (SCT) shortens life or predispose to disease. Therefore, we examined whether SCT-carriers had increased risk of death or diseases linked to SCT. We studied 467,779 general population individuals from the UK Biobank. All had whole-exome sequencing performed and were followed prospectively for a median of 15 years. Individuals with SCT (n=1,253) were not at increased risk of all-cause death (hazard ratio[HR]:1.04;95%CI:0.84-1.29), cardiovascular death (1.34;0.90-2.00), or for having myocardial infarction (0.72;0.42-1.24), ischemic stroke (1.30;0.88-1.94), pulmonary embolism (1.29;0.84-1.99), or heart failure (0.79;0.55-1.14) compared to non-carriers. However, SCT-carriers had increased risk of diabetes (HR:1.30;95%CI:1.12-1.50), chronic kidney disease (HR:1.46;95%CI:1.18-1.80), and hypertension (odds ratio:1.24;95%CI:1.08-1.42). Surprisingly, risk of cardiovascular death was increased in SCT-carriers with diabetes when compared to non-carriers with diabetes (HR:2.17;95%CI:1.14-4.12). To examine whether selection bias may explain why previous studies based on hospital-diagnosed SCT found increased risk of cardiovascular disease, we repeated our analyses using hospital diagnoses of SCT from national registries, instead of defining SCT from genotyping. Individuals registered as SCT-carriers in hospital registries had markedly increased risk of all-cause death (HR:2.24;95%CI:1.42-3.52) and ischemic stroke (2.92;1.30-6.60), likely due to selection bias. In conclusion, SCT-carriers were not at increased risk of all-cause death or cardiovascular disease.


  • Open Access

    Osteoarthritis and analgesic consumption in haemochromatosis HFE C282Y homozygotes with normal or low iron parameters

    by Jens Helby, Mathis Mottelson, Stig Egil Bojesen, Børge Grønne Nordestgaard, Mikkel Faurschou, Jesper Petersen, Christina Ellervik, Marie Warny, Andreas Glenthøj

    We studied 132,525 Danish general population individuals to examine whether risk of osteoarthritis and/or use of pain-relieving medication was increased in haemochromatosis C282Y homozygotes with normal or low plasma iron, transferrin saturation, or ferritin. We genotyped all 132,525 individuals for the HFE C282Y and H63D variants. During a median follow-up of 40 years, 31,636 individuals had osteoarthritis. Risk of osteoarthritis was increased even in C282Y homozygotes with normal or low plasma iron (hazard ratio:1.37;95% confidence interval:1.12-1.68 compared to non-carriers with normal/low iron), transferrin saturation (1.55;1.10-2.16), or ferritin (1.96;1.11-3.45). Here we show that risk of osteoarthritis is increased in those C282Y homozygotes not usually recommended for genotyping according to clinical guidelines, challenging the presumption that the increased risk of osteoarthritis is mainly caused by systemic iron accumulation. Indeed, C282Y homozygotes with normal or low ferritin levels had a particularly high cumulative incidence of any osteoarthritis (24% at age 60 years, 60% at age 80 years).


  • Open Access

    Risk of fractures according to iron parameters and hemochromatosis HFE genotype in 142,146 general population individuals

    by Marie Warny, Andreas Glenthøj, Børge Grønne Nordestgaard, Mathis Mottelson, Christina Ellervik, Jesper Petersen, Stig Egil Bojesen, Jens Helby

    Risk of fractures may be increased in individuals with iron deficiency, iron overload, and/or HFE hemochromatosis. To test this hypothesis, we followed 142,146 Danish general population individuals for a median of 11 years (range:0-41) after study enrolment for hospital and emergency room admissions with fractures. All individuals had blood samples drawn at study enrolment. We measured iron, transferrin saturation, and ferritin in 136,611, 136,555, and 37,990 individuals, respectively, while 132,499 individuals were genotyped for the HFE C282Y and H63D variants. We found a U-shaped relationship between fracture risk and concentrations of plasma iron and transferrin saturation when studying all individuals irrespective of genotype. When studied according to plasma ferritin, fracture risk was increased in individuals with low ferritin concentrations, while risk was not increased in individuals with high concentrations. When compared to non-carriers, HFE C282Y homozygotes had increased risk of any fracture (hazard ratio[HR]:1.38;95%CI:1.09-1.75;p=0.008), and risk was increased even in C282Y homozygotes with normal ferritin concentrations (HR:2.89;95%CI:1.50-5.56), which is important as these individuals would not usually be recommended for HFE genotyping according to clinical guidelines. When compared to non-carriers, risk of fracture of the hip and femur was increased in C282Y homozygotes (HR:1.78;95%CI:1.17-2.70;p=0.007) but surprisingly also in H63D homozygotes (HR:1.21;95%CI:1.00-1.47;p=0.04), C282Y heterozygotes (HR:1.10;95%CI:1.00-1.21;p=0.04), and C282Y/H63D compound heterozygotes (HR:1.23;95%CI:1.00-1.51;p=0.05). The markedly increased fracture risk in C282Y homozygotes with normal ferritin may challenge the presumption that systemic iron accumulation is the primary mechanism causing their increased fracture risk. Further studies are needed to examine whether phlebotomy reduces fracture risk.


  • Open Access

    C282Y Homozygosity Increases Erythrocyte Turnover and Decreases HbA1c—A Population-Based Study

    by Rebekka Hillingsø, Alisa Devedzic Kjaergaard, Morten Kranker Larsen, Thomas Mandrup-Poulsen, Henrik Enghusen Poulsen, Mathis Mottelson, Jesper Brix Petersen, Børge Grønne Nordestgaard, Hans Carl Hasselbalch, Stig Egil Bojesen, et al.

    Individuals with C282Y/C282Y in the hemochromatosis HFE gene have increased iron levels, which catalyze the formation of reactive oxygen species, and an increased risk of diabetes. These individuals may have disproportionately lower hemoglobin A1c (HbA1c) due to increased erythrocyte turnover, decreased erythrocyte counts, and/or an increased mean corpuscular hemoglobin concentration (MCHC). In the Copenhagen General Population Study (N = 103,734) and the Danish General Suburban Population Study (GESUS, N = 20,003), we investigated the association between C282Y/C282Y (N = 399) and other HFE genotypes with erythrocyte count, MCHC, mean corpuscular volume (MCV), red cell distribution width (RDW), and high-sensitivity C-reactive protein (hsCRP). In GESUS, we additionally investigated the association with oxidative stress (by 8-oxo-7,8-dihydroguanosine and 8-oxo-7,8-dihydro-2′-deoxyguanosine), reticulocyte count, reticulocyte hemoglobin, reticulocyte percentage as a proxy for erythrocyte turnover, and HbA1c in linear regressions adjusted for age, sex, cohort, and blood donation. We investigated the mediation between HFE genotype and HbA1c. Compared to non-carriers, individuals with C282Y/C282Y had increased p-iron, transferrin saturation, ferritin, hsCRP, oxidative stress, reticulocyte counts, reticulocyte percentage (1.24% vs. 1.06%, p = 1.7 × 10−5) as a proxy for erythrocyte turnover, MCHC (344 vs. 340 g/L, p = 1.7 × 10−12), MCH, MCV, reticulocyte hemoglobin, p-glucose (5.6 vs. 5.4, p = 0.007), bilirubin, and LDH and decreased RDW, erythrocyte counts (4.49 × 1012/L vs. 4.61 × 1012/L, p = 6.1 × 10−11), estimated erythrocyte survival, and HbA1c (36 vs. 38 mmol/mol, p = 0.01). The associations were similar, although attenuated, for other HFE genotypes. The association between the HFE genotype and decreased HbA1c was partially mediated by increased transferrin saturation, MCHC, MCV, and decreased erythrocyte count, but not by hsCRP, reticulocyte count, oxidative stress, or blood donation. In conclusion, while C282Y/C282Y and other HFE genotypes increased erythrocyte turnover, the disproportionately decreased HbA1c level was explained by fewer but larger erythrocytes filled with more hemoglobin and removed earlier from circulation, thus diluting the relative concentration of intracellular glucose per hemoglobin molecule.

  • Open Access

    Accurate diagnosis of hemoglobinopathies with machine learning based on high‐throughput proteomics

    by Shaodong Wei, Annelaura Bach Nielsen, Jens Helby, Lylia Drici, Christine Rasmussen, Juanjuan Wang, Matthias Mann, Jesper Petersen, Nicolai J. Wewer Albrechtsen, Andreas Glenthøj

    Hemoglobinopathies, such as sickle cell disease and thalassemias, impose a substantial global burden, particularly in endemic regions. Current diagnostic methods, such as high‐performance liquid chromatography (HPLC), capillary electrophoresis, and genetic testing, can be time‐consuming, expensive, or limited in detecting all variants. This study introduces a novel diagnostic framework that combines high‐throughput proteomics with machine learning to address these challenges. We processed red blood cells, whole blood, and plasma samples from 82 individuals (development cohort) and 45 individuals (validation cohort) with structural hemoglobin variants (hemoglobin S, hemoglobin C, hemoglobin D, and hemoglobin E) or β‐thalassemia trait, as confirmed by standard clinical testing. Tryptic peptides were analyzed using data‐independent acquisition mass spectrometry, and random forest classifiers were trained to identify structural variants or β‐thalassemia trait. Model performance was evaluated across 100 Monte Carlo cross‐validations. For structural variants, the classifier achieved an area under the receiver‐operating characteristic curve (AUC) of 1.000 and 99.9% prediction accuracy in the validation cohort, when comparing our proteomics‐based diagnostics to standard testing with HPLC and Sanger sequencing (gold standard). For β‐thalassemia trait, the mean AUC was 1.000, and the prediction accuracy was 96.9% in the validation cohort, and a single peptide alone yielded 92% accuracy in a simple decision tree. This high‐throughput proteomics approach offers a rapid, scalable, and potentially cost‐effective alternative to existing diagnostic workflows, requiring minimal sample preparation while reducing manual interpretation. By combining peptide‐level data with machine learning, it enables precise classification of hemoglobinopathies and demonstrates a compelling path for routine clinical evaluation of hereditary anemias.


  • Open Access

    Machine Learning‐Based Detection of HbS and HbC Carriers in the UK General Population

    by Frederik Christensen, Deniz Kenan Kılıç, Alexander Djupnes Fuglkjær, Jesper Petersen, Tarec Christoffer El‐Galaly, Andreas Glenthøj, Jens Helby, Izabela Ewa Nielsen

    Background: Haemoglobin S (HbS) and C (HbC) are the most important sickling variants on the African continent, imposing major health burdens. Early detection of carrier status is crucial but often hindered by resource limitations. Objectives: To develop machine learning (ML) models to accurately classify HbS and HbC carriers using readily available routine blood tests, facilitating cost‐effective mass screening. Methods: We utilised demographic and routine blood parameters from 469,248 individuals from the UK general population, including 1635 individuals with HbS and/or HbC variants identified by whole exome sequencing, to develop ML models for carrier detection based on standard blood tests. Three ML models (Logistic Regression [LR], Random Forest [RF] and XGBoost [XGB]) were trained using 32 different standard blood test results. Results: All models demonstrated high discriminatory ability (ROC‐AUC: LR 0.951; RF 0.943; XGB 0.956) in the UK general population. At a sensitivity of 95%, specificities were 77% (LR), 76% (RF) and 78% (XGB). SHAP analysis revealed consistent key features across models. When use was restricted to black individuals, performance fell considerably. Conclusions: ML models based on routine blood tests effectively identify HbS and HbC carriers in a mixed general population. This approach has the potential to enhance screening efficiency by reducing reliance on specialised techniques.